Merck Animal Health’s Recent Acquisition Wins Four Technology Association of Iowa Prometheus Awards

Madison, N.J., April 21, 2016 – Merck Animal Health is pleased to announce that Harrisvaccines, which was acquired by the company in November, received the Technology Association of Iowa (TIA) 2016 Prometheus Awards for Best User of Technology, Life Sciences Company of the Year and Small/Medium Technology Company of the Year.
“This recognition from the TIA distinguishes the team’s pioneering spirit and commitment to the advancement of our technology and product offerings,” said Shannon Kellner, Associate Vice President, Merck Animal Health. “As a leader in biologics, we have built a robust portfolio of vaccines across all animal species. Combine those products with our newly acquired technologies, and our strong capabilities and global reach, and we are well positioned to meet the continually evolving health needs of our customers and reinforce our commitment to the science of healthier animals.”
In addition, Mark Mogler, Ph.D., Principal Scientist, Biology-Discovery, was named “Chief Scientific Officer of the Year”, honored for his role in developing Harrisvaccines’ most impactful product in 2015 – Avian Influenza Vaccine, RNA. Highly Pathogenic Avian Influenza (HPAI) killed more than 50 million chickens and turkeys in the United States last year. This vaccine could be instrumental in minimizing the impact of similar outbreaks in the future.
“I am incredibly honored to be recognized by the TIA,” said Dr. Mogler. “My role in the development of the HPAI vaccine was a significant career milestone, and I look forward to continuing to identify innovative vaccine technologies that will help protect animals’ health and improve customers’ bottom lines. I take great pride in the work our team does to deliver meaningful solutions.”
The Prometheus Awards are Iowa’s largest and most prestigious honor, recognizing and celebrating the innovation and brilliance of Iowa’s high-tech industry, as well as companies and individuals who have demonstrated outstanding leadership and excellence in technology.

About Merck Animal Health

For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (